- Home
- BSBR vs ONC Comparison
BSBR vs ONC Comparison
Compare BSBR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSBR
- ONC
- Stock Information
- Founded
- BSBR 1985
- ONC 2010
- Country
- BSBR Brazil
- ONC Switzerland
- Employees
- BSBR N/A
- ONC N/A
- Industry
- BSBR Commercial Banks
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- BSBR Finance
- ONC Health Care
- Exchange
- BSBR Nasdaq
- ONC Nasdaq
- Market Cap
- BSBR 40.6B
- ONC 37.3B
- IPO Year
- BSBR 2009
- ONC N/A
- Fundamental
- Price
- BSBR $5.39
- ONC $342.50
- Analyst Decision
- BSBR Strong Buy
- ONC Strong Buy
- Analyst Count
- BSBR 2
- ONC 10
- Target Price
- BSBR $6.00
- ONC $340.70
- AVG Volume (30 Days)
- BSBR 583.9K
- ONC 297.4K
- Earning Date
- BSBR 10-28-2025
- ONC 11-11-2025
- Dividend Yield
- BSBR 3.97%
- ONC N/A
- EPS Growth
- BSBR 27.22
- ONC N/A
- EPS
- BSBR 0.36
- ONC N/A
- Revenue
- BSBR $9,124,703,234.00
- ONC $4,562,002,000.00
- Revenue This Year
- BSBR N/A
- ONC $896.81
- Revenue Next Year
- BSBR N/A
- ONC N/A
- P/E Ratio
- BSBR $7.53
- ONC N/A
- Revenue Growth
- BSBR 11.13
- ONC 47.33
- 52 Week Low
- BSBR $3.75
- ONC $170.99
- 52 Week High
- BSBR $5.65
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- BSBR 49.93
- ONC 57.00
- Support Level
- BSBR $5.38
- ONC $334.53
- Resistance Level
- BSBR $5.49
- ONC $355.30
- Average True Range (ATR)
- BSBR 0.10
- ONC 7.30
- MACD
- BSBR -0.02
- ONC 0.00
- Stochastic Oscillator
- BSBR 17.19
- ONC 61.75
About BSBR Banco Santander Brasil SA each representing one unit
Banco Santander (Brasil) SA is part of Santander Group, a Spanish bank. It operates across two segments; the Commercial Banking segment, catering to both individual and corporate client and the Global Wholesale Banking segment, which encompasses Investment Banking and Markets operations, including the Treasury and Equity Business Departments. The bank generates majority of its revenue from the Commercial Banking segment and has operations in Brazil and internationally.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.